Trial Profile
A integrated genomic analysis study investigating the effect of erlotinib in patients with EGFR-mutant non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 19 Dec 2015 New trial record